米那普明和帕罗西汀治疗后抑郁症患者出现的治疗后新发不良事件。 - Suppr

Suppr

超能文献

Post-treatment emergent adverse events in depressed patients following treatment with milnacipran and paroxetine.

作者信息

Vandel P, Sechter D, Weiller E, Pezous N, Cabanac F, Tournoux A, Panconi E

出版信息

Hum Psychopharmacol. 2004 Dec;19(8):585-6. doi: 10.1002/hup.644.

DOI:10.1002/hup.644

PMID:15570574

Abstract

摘要

相似文献

Post-treatment emergent adverse events in depressed patients following treatment with milnacipran and paroxetine.

Hum Psychopharmacol. 2004 Dec;19(8):585-6. doi: 10.1002/hup.644.

A comparative study of milnacipran and paroxetine in outpatients with major depression.

J Affect Disord. 2004 Dec;83(2-3):233-6. doi: 10.1016/j.jad.2004.07.002.

Differential effects of milnacipran, fluvoxamine and paroxetine for depression, especially in gender.

Eur Psychiatry. 2003 Dec;18(8):418-20. doi: 10.1016/j.eurpsy.2003.05.002.

Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression: a summary of clinical trial results.

Int Clin Psychopharmacol. 1996 Sep;11 Suppl 4:35-9. doi: 10.1097/00004850-199609004-00005.

Effects of paroxetine or milnacipran on serum brain-derived neurotrophic factor in depressed patients.

Prog Neuropsychopharmacol Biol Psychiatry. 2007 Jun 30;31(5):1034-7. doi: 10.1016/j.pnpbp.2007.03.001. Epub 2007 Mar 7.

Milnacipran and selective serotonin reuptake inhibitors in major depression.

Int Clin Psychopharmacol. 1996 Sep;11 Suppl 4:41-6. doi: 10.1097/00004850-199609004-00006.

Double-blind study of the efficacy and safety of milnacipran and imipramine in elderly patients with major depressive episode.

Acta Psychiatr Scand. 1998 Feb;97(2):157-65. doi: 10.1111/j.1600-0447.1998.tb09980.x.

Efficacy and tolerability of milnacipran: an overview.

Int Clin Psychopharmacol. 1996 Sep;11 Suppl 4:47-51. doi: 10.1097/00004850-199609004-00007.

Milnacipran for fibromyalgia.

Issues Emerg Health Technol. 2008 Feb(114):1-4.

Effects of milnacipran and paroxetine on overactive bladder due to neurologic diseases: a urodynamic assessment.

Urol Int. 2008;81(3):335-9. doi: 10.1159/000151415. Epub 2008 Oct 16.

引用本文的文献

Incidence and risk factors of antidepressant withdrawal symptoms: a meta-analysis and systematic review.

Mol Psychiatry. 2025 May;30(5):1758-1769. doi: 10.1038/s41380-024-02782-4. Epub 2024 Oct 11.

Antidepressant Withdrawal and Rebound Phenomena.

Dtsch Arztebl Int. 2019 May 17;116(20):355-361. doi: 10.3238/arztebl.2019.0355.

Paroxetine versus other anti-depressive agents for depression.

Cochrane Database Syst Rev. 2014 Apr 3;2014(4):CD006531. doi: 10.1002/14651858.CD006531.pub2.

Double-blind, comparative study of milnacipran and paroxetine in Japanese patients with major depression.

Neuropsychiatr Dis Treat. 2013;9:555-65. doi: 10.2147/NDT.S42915. Epub 2013 Apr 26.

Milnacipran: a unique antidepressant?

Neuropsychiatr Dis Treat. 2010 Sep 7;6(Suppl I):23-31. doi: 10.2147/NDT.S11777.

Milnacipran versus other antidepressive agents for depression.

Cochrane Database Syst Rev. 2009 Jul 8;2009(3):CD006529. doi: 10.1002/14651858.CD006529.pub2.

Why does milnacipran produce so few discontinuation syndromes following abrupt withdrawal?

Neuropsychiatr Dis Treat. 2007 Feb;3(1):181-2. doi: 10.2147/nedt.2007.3.1.181.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Post-treatment emergent adverse events in depressed patients following treatment with milnacipran and paroxetine.

Hum Psychopharmacol. 2004 Dec;19(8):585-6. doi: 10.1002/hup.644.

A comparative study of milnacipran and paroxetine in outpatients with major depression.

J Affect Disord. 2004 Dec;83(2-3):233-6. doi: 10.1016/j.jad.2004.07.002.

Differential effects of milnacipran, fluvoxamine and paroxetine for depression, especially in gender.

Eur Psychiatry. 2003 Dec;18(8):418-20. doi: 10.1016/j.eurpsy.2003.05.002.

Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression: a summary of clinical trial results.

Int Clin Psychopharmacol. 1996 Sep;11 Suppl 4:35-9. doi: 10.1097/00004850-199609004-00005.

Effects of paroxetine or milnacipran on serum brain-derived neurotrophic factor in depressed patients.

Prog Neuropsychopharmacol Biol Psychiatry. 2007 Jun 30;31(5):1034-7. doi: 10.1016/j.pnpbp.2007.03.001. Epub 2007 Mar 7.

Milnacipran and selective serotonin reuptake inhibitors in major depression.

Int Clin Psychopharmacol. 1996 Sep;11 Suppl 4:41-6. doi: 10.1097/00004850-199609004-00006.

Double-blind study of the efficacy and safety of milnacipran and imipramine in elderly patients with major depressive episode.

Acta Psychiatr Scand. 1998 Feb;97(2):157-65. doi: 10.1111/j.1600-0447.1998.tb09980.x.

Efficacy and tolerability of milnacipran: an overview.

Int Clin Psychopharmacol. 1996 Sep;11 Suppl 4:47-51. doi: 10.1097/00004850-199609004-00007.

Milnacipran for fibromyalgia.

Issues Emerg Health Technol. 2008 Feb(114):1-4.

Effects of milnacipran and paroxetine on overactive bladder due to neurologic diseases: a urodynamic assessment.

Urol Int. 2008;81(3):335-9. doi: 10.1159/000151415. Epub 2008 Oct 16.

引用本文的文献

Incidence and risk factors of antidepressant withdrawal symptoms: a meta-analysis and systematic review.

Mol Psychiatry. 2025 May;30(5):1758-1769. doi: 10.1038/s41380-024-02782-4. Epub 2024 Oct 11.

Antidepressant Withdrawal and Rebound Phenomena.

Dtsch Arztebl Int. 2019 May 17;116(20):355-361. doi: 10.3238/arztebl.2019.0355.

Paroxetine versus other anti-depressive agents for depression.

Cochrane Database Syst Rev. 2014 Apr 3;2014(4):CD006531. doi: 10.1002/14651858.CD006531.pub2.

Double-blind, comparative study of milnacipran and paroxetine in Japanese patients with major depression.

Neuropsychiatr Dis Treat. 2013;9:555-65. doi: 10.2147/NDT.S42915. Epub 2013 Apr 26.

Milnacipran: a unique antidepressant?

Neuropsychiatr Dis Treat. 2010 Sep 7;6(Suppl I):23-31. doi: 10.2147/NDT.S11777.

Milnacipran versus other antidepressive agents for depression.

Cochrane Database Syst Rev. 2009 Jul 8;2009(3):CD006529. doi: 10.1002/14651858.CD006529.pub2.

Why does milnacipran produce so few discontinuation syndromes following abrupt withdrawal?

Neuropsychiatr Dis Treat. 2007 Feb;3(1):181-2. doi: 10.2147/nedt.2007.3.1.181.